IMMUNITYBIO, INC. Other Operating Activities, Cash Flow Statement
IMMUNITYBIO, INC. (IBRX) reported Other Operating Activities, Cash Flow Statement of -$218.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherOperatingActivitiesCashFlowStatement · last filed 2026-08-04
- IMMUNITYBIO, INC. other operating activities, cash flow statement for the quarter ending 2026-06-30 was -$234.00K, a 211.43% decline year-over-year.
- IMMUNITYBIO, INC. other operating activities, cash flow statement for the quarter ending 2026-03-31 was $16.00K, a 93.42% decline year-over-year.
- IMMUNITYBIO, INC. other operating activities, cash flow statement for the quarter ending 2025-12-31 was $82.00K.
- IMMUNITYBIO, INC. other operating activities, cash flow statement for the quarter ending 2025-09-30 was $35.00K, a 5.41% decline year-over-year.
- IMMUNITYBIO, INC. other operating activities, cash flow statement for fiscal 2025 was $570.00K, a 422.94% increase from fiscal 2024.
- IMMUNITYBIO, INC. other operating activities, cash flow statement for fiscal 2024 was $109.00K.
- IMMUNITYBIO, INC. other operating activities, cash flow statement for fiscal 2023 was -$258.00K, a 195.91% decline from fiscal 2022.
- IMMUNITYBIO, INC. other operating activities, cash flow statement for fiscal 2022 was $269.00K, a 63.70% decline from fiscal 2021.
| Period end | Other Operating Activities, Cash Flow Statement 3 month | Other Operating Activities, Cash Flow Statement 3 month as first filed | Other Operating Activities, Cash Flow Statement 6 month | Other Operating Activities, Cash Flow Statement 6 month as first filed | Other Operating Activities, Cash Flow Statement 9 month | Other Operating Activities, Cash Flow Statement 12 month | Other Operating Activities, Cash Flow Statement 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$234.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$218.00K 10-Q · filed 2026-08-04 | -$136.00K derived: sum of 3 quarters · filed 2026-08-04 | -$101.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $16.00K 10-Q · filed 2026-05-07 | $98.00K derived: sum of 2 quarters · filed 2026-05-07 | $133.00K derived: sum of 3 quarters · filed 2026-05-07 | $343.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $117.00K derived: sum of 2 quarters · filed 2026-02-23 | $327.00K derived: sum of 3 quarters · filed 2026-08-04 | $570.00K 10-K · filed 2026-02-23 | |||
| 2025-09-30 | $35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $245.00K derived: sum of 2 quarters · filed 2026-08-04 | $488.00K 10-Q · filed 2025-11-05 | $451.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $453.00K 10-Q · filed 2026-08-04 | $416.00K derived: sum of 3 quarters · filed 2026-08-04 | $453.00K derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $243.00K 10-Q · filed 2026-05-07 | $242.00K 10-Q · filed 2025-05-12 | $206.00K derived: sum of 2 quarters · filed 2026-05-07 | $243.00K derived: sum of 3 quarters · filed 2026-05-07 | $278.00K derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $35.00K derived: sum of 3 quarters · filed 2026-02-23 | $109.00K 10-K · filed 2026-02-23 | |||
| 2024-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $72.00K derived: sum of 2 quarters · filed 2025-11-05 | $146.00K 10-Q · filed 2025-11-05 | $347.00K derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2024-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $109.00K 10-Q · filed 2025-08-05 | $94.00K 10-Q · filed 2024-08-12 | $310.00K derived: sum of 3 quarters · filed 2026-02-23 | -$272.00K derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-03-31 | $74.00K 10-Q · filed 2025-05-12 | $275.00K derived: sum of 2 quarters · filed 2026-02-23 | -$307.00K derived: sum of 3 quarters · filed 2026-02-23 | -$295.00K derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$381.00K derived: sum of 2 quarters · filed 2026-02-23 | -$369.00K derived: sum of 3 quarters · filed 2026-02-23 | -$258.00K 10-K · filed 2026-02-23 | -$407.00K 10-K · filed 2024-03-19 | ||
| 2023-09-30 | -$582.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$570.00K derived: sum of 2 quarters · filed 2024-11-12 | -$459.00K 10-Q · filed 2024-11-12 | -$63.00K derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $123.00K 10-Q · filed 2024-08-12 | $519.00K derived: sum of 3 quarters · filed 2025-03-03 | $170.00K derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-03-31 | $111.00K 10-Q · filed 2024-05-09 | $507.00K derived: sum of 2 quarters · filed 2025-03-03 | $158.00K derived: sum of 3 quarters · filed 2025-03-03 | -$665.00K derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2022-12-31 | $396.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $47.00K derived: sum of 2 quarters · filed 2025-03-03 | -$776.00K derived: sum of 3 quarters · filed 2025-03-03 | $269.00K 10-K · filed 2025-03-03 | $273.00K 10-K · filed 2023-03-01 | ||
| 2022-09-30 | -$349.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.17M derived: sum of 2 quarters · filed 2023-11-09 | -$127.00K 10-Q · filed 2023-11-09 | $921.00K derived: sum of 4 quarters · filed 2024-03-19 | |||
| 2022-06-30 | -$823.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $222.00K 10-Q · filed 2023-08-08 | $25.00K 10-Q · filed 2022-08-08 | $1.27M derived: sum of 3 quarters · filed 2024-03-19 | $1.25M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2022-03-31 | $1.04M 10-Q · filed 2023-05-11 | $848.00K 10-Q · filed 2022-05-10 | $2.09M derived: sum of 2 quarters · filed 2024-03-19 | $2.08M derived: sum of 3 quarters · filed 2024-03-19 | $1.69M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2021-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.03M derived: sum of 2 quarters · filed 2024-03-19 | $641.00K derived: sum of 3 quarters · filed 2024-03-19 | $741.00K 10-K · filed 2024-03-19 | $349.00K 10-K · filed 2022-03-01 | ||
| 2021-09-30 | -$16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$407.00K derived: sum of 2 quarters · filed 2022-11-09 | -$307.00K 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | -$391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$291.00K 10-Q · filed 2022-08-08 | |||||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-10 | -$125.00K 10-Q · filed 2021-05-14 | |||||
| 2020-12-31 | $446.00K 10-K · filed 2023-03-01 | ||||||
| 2020-03-31 | $4.00K 10-Q · filed 2021-05-14 | ||||||
| 2019-12-31 | $890.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |